Skip to main content

Table 1 Baseline characteristics by dosage and treatment arm

From: Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

Characteristic

0.05 mg/d

0.15 mg/d

0.5 mg/d

1.5 mg/d

5.0 mg/d

 

P/R

(N = 43)

R/P

(N = 44)

P/R

(N = 44)

R/P

(N = 44)

P/R

(N = 41)

R/P

(N = 44)

P/R

(N = 44)

R/P

(N = 44)

P/R

(N = 44)

R/P

(N = 43)

Mean (± SD) of baseline characteristic

          

   Age, years

48.1 ± 7.8

50.4 ± 7.4

46.8 ± 8.6

48.2 ± 8.0

48.8 ± 7.2

49.7 ± 7.5

49.0 ± 6.7

48.5 ± 8.5

49.7 ± 7.9

44.9 ± 8.4

   BMI, kg/m2

27.1 ± 2.7

27.6 ± 2.3

26.4 ± 2.7

26.9 ± 2.2

26.3 ± 2.7

27.0 ± 2.5

25.9 ± 3.0

26.9 ± 2.4

25.8 ± 2.5

26.7 ± 2.7

   Pulse rate, beats/min

77.0 ± 10.8

77.6 ± 10.3

75.8 ± 12.8

74.4 ± 9.8

75.2 ± 11.0

76.8 ± 12.3

74.2 ± 11.8

80.5 ± 11.5

75.8 ± 13.0

77.3 ± 10.0

   Systolic BP, mm Hg

          

Office

148.7 ± 7.3

150.9 ± 7.4

148.0 ± 5.8

150.5 ± 8.4

150.4 ± 7.6

152.5 ± 8.7

150.8 ± 7.6

151.1 ± 7.8

150.6 ± 6.7

149.4 ± 7.2

24-h ambulatory*

136.8 ± 9.5

137.3 ± 11.3

135.3 ± 10.4

134.9 ± 10.9

140.9 ± 11.0

137.4 ± 9.6

138.1 ± 11.2

137.8 ± 11.8

138.6 ± 11.4

136.2 ± 11.7

Daytime*

144.4 ± 9.9

143.7 ± 12.5

141.8 ± 10.4

142.3 ± 12.3

147.1 ± 12.7

142.9 ± 10.1

145.0 ± 13.6

144.5 ± 12.5

145.2 ± 12.6

142.2 ± 12.7

Night-time*

122.2 ± 11.9

123.5 ± 13.8

122.5 ± 14.8

119.9 ± 11.3

126.4 ± 12.2

125.6 ± 12.6

125.7 ± 11.7

123.5 ± 14.7

125.5 ± 13.0

122.8 ± 15.4

   Diastolic BP, mm Hg

          

Office

92.1 ± 7.6

93.0 ± 7.0

91.9 ± 7.2

92.4 ± 7.2

92.3 ± 6.9

95.9 ± 7.2

92.0 ± 7.9

94.2 ± 8.2

92.8 ± 6.4

93.9 ± 6.5

24-h ambulatory*

85.5 ± 7.9

84.1 ± 7.2

84.5 ± 7.6

84.2 ± 8.4

88.1 ± 9.4

87.6 ± 8.8

86.5 ± 7.3

85.6 ± 8.4

86.9 ± 7.0

85.0 ± 9.0

Daytime*

91.6 ± 8.2

89.7 ± 8.8

90.2 ± 7.5

90.2 ± 9.5

93.2 ± 10.9

92.3 ± 9.1

91.5 ± 8.8

91.0 ± 8.8

92.5 ± 8.3

89.6 ± 10.0

Night-time*

73.4 ± 9.7

72.7 ± 8.4

74.3 ± 10.8

72.3 ± 7.8

77.1 ± 9.5

78.4 ± 10.8

77.1 ± 8.6

74.7 ± 11.0

76.6 ± 7.7

74.2 ± 10.5

Number (%) with baseline characteristic

          

   Women

20 (46.5)

18 (40.9)

21 (47.7)

15 (34.1)

12 (29.3)

14 (31.8)

21 (47.7)

16 (36.4)

22 (50.0)

18 (41.9)

   Caucasian

43 (100)

44 (100)

44 (100)

44 (100)

41 (100)

42 (95.5)

43 (97.7)

43 (97.7)

44 (100)

43 (100)

   Previous AH treatment

14 (32.6)

14 (31.8)

22 (50.0)

20 (45.5)

18 (43.9)

24 (54.5)

23 (52.3)

22 (50.0)

18 (40.9)

18 (41.9)

   Current smokers

5 (11.6)

7 (15.9)

6 (13.6)

9 (20.5)

6 (14.6)

8 (18.2)

5 (11.4)

7 (15.9)

14 (31.8)

12 (27.9)

   Current alcohol intake

21 (48.8)

23 (52.3)

19 (43.2)

23 (52.3)

22 (53.7)

21 (47.7)

18 (40.9)

23 (52.3)

20 (45.5)

27 (62.8)

  1. Values are means ± SD or number (percentage) of patients. N indicates the number of patients. Abbreviations: P/R, 5 weeks placebo followed by 5 weeks rostafuroxin; A/R, 5 weeks rostafuroxin followed by 5 weeks placebo; BP, blood pressure; AH, antihypertensive before the run-in period.
  2. *Ambulatory blood pressure recordings were available in 383 patients.